Tiliroside Protects against Lipopolysaccharide-Induced Acute Kidney Injury via Intrarenal Renin-Angiotensin System in Mice.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
25 Oct 2023
Historique:
received: 31 07 2023
revised: 03 10 2023
accepted: 06 10 2023
medline: 15 11 2023
pubmed: 14 11 2023
entrez: 14 11 2023
Statut: epublish

Résumé

Tiliroside, a natural flavonoid, has various biological activities and improves several inflammatory diseases in rodents. However, the effect of Tiliroside on lipopolysaccharide (LPS)-induced acute kidney injury (AKI) and the underlying mechanisms are still unclear. This study aimed to evaluate the potential renoprotective effect of Tiliroside on LPS-induced AKI in mice. Male C57BL/6 mice were intraperitoneally injected with LPS (a single dose, 3 mg/kg) with or without Tiliroside (50 or 200 mg/kg/day for 8 days). Tiliroside administration protected against LPS-induced AKI, as reflected by ameliorated renal dysfunction and histological alterations. LPS-stimulated renal expression of inflammatory cytokines, fibrosis markers, and kidney injury markers in mice was significantly abolished by Tiliroside. This flavonoid also stimulated autophagy flux but inhibited oxidative stress and tubular cell apoptosis in kidneys from LPS-injected mice. Mechanistically, our study showed the regulation of Tiliroside on the intrarenal renin-angiotensin system in LPS-induced AKI mice. Tiliroside treatment suppressed intrarenal AGT, Renin, ACE, and Ang II, but upregulated intrarenal ACE2 and Ang1-7, without affecting plasma Ang II and Ang1-7 levels. Collectively, our data highlight the renoprotective action of Tiliroside on LPS-induced AKI by suppressing inflammation, oxidative stress, and tubular cell apoptosis and activating autophagy flux via the shift towards the intrarenal ACE2/Ang1-7 axis and away from the intrarenal ACE/Ang II axis.

Identifiants

pubmed: 37958538
pii: ijms242115556
doi: 10.3390/ijms242115556
pmc: PMC10648967
pii:
doi:

Substances chimiques

Lipopolysaccharides 0
tiliroside 15M04TXR9M
Peptidyl-Dipeptidase A EC 3.4.15.1
Angiotensin-Converting Enzyme 2 EC 3.4.17.23
Flavonoids 0
Angiotensin II 11128-99-7

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : National Natural Science Foundation of China
ID : 82160051 and 32100908

Références

J Am Soc Nephrol. 2017 Apr;28(4):1040-1049
pubmed: 28255001
Ren Fail. 2013;35(2):291-4
pubmed: 23181751
J Am Soc Nephrol. 2017 May;28(5):1350-1361
pubmed: 28151411
J Cell Physiol. 2019 Sep;234(9):16263-16274
pubmed: 30815860
Antioxid Redox Signal. 2021 Apr 1;34(10):784-799
pubmed: 32323554
Mol Neurobiol. 2018 Oct;55(10):8103-8123
pubmed: 29508282
Cell Death Dis. 2021 Jun 3;12(6):572
pubmed: 34083513
Antioxid Redox Signal. 2005 Sep-Oct;7(9-10):1327-36
pubmed: 16115038
Cells. 2020 Jul 17;9(7):
pubmed: 32709045
Front Immunol. 2023 May 05;14:1180866
pubmed: 37215112
Acta Physiol (Oxf). 2023 Jan;237(1):e13899
pubmed: 36264268
Hypertension. 2022 Jun;79(6):1190-1202
pubmed: 35296155
Am J Physiol Renal Physiol. 2020 May 1;318(5):F1122-F1135
pubmed: 32174138
Compr Rev Food Sci Food Saf. 2018 Sep;17(5):1395-1421
pubmed: 33350157
Planta Med. 2013 Aug;79(12):1003-8
pubmed: 23877918
Kidney Int. 2023 Jun;103(6):1041-1055
pubmed: 37030663
Int J Pharm. 2019 Oct 30;570:118642
pubmed: 31446024
Front Pharmacol. 2019 Apr 18;10:376
pubmed: 31057404
Antioxid Redox Signal. 2013 Jan 1;18(1):19-35
pubmed: 22662869
Adv Exp Med Biol. 2020;1207:469-480
pubmed: 32671769
J Nat Prod. 2020 Mar 27;83(3):770-803
pubmed: 32162523
Cell Rep. 2020 Oct 20;33(3):108245
pubmed: 33086058
Lab Invest. 2019 Dec;99(12):1770-1783
pubmed: 31278346
J Comput Aided Mol Des. 2010 May;24(5):417-22
pubmed: 20401516
Exp Ther Med. 2016 Jul;12(1):499-505
pubmed: 27347085
Diabetologia. 2013 May;56(5):1155-65
pubmed: 23344731
Molecules. 2020 Dec 03;25(23):
pubmed: 33287398
Int J Mol Sci. 2019 Sep 04;20(18):
pubmed: 31487867
Nutrients. 2013 Aug 28;5(9):3367-87
pubmed: 23989753
Iran J Pharm Res. 2019 Fall;18(4):1931-1946
pubmed: 32184859
Biol Pharm Bull. 2019;42(1):18-25
pubmed: 30606987
Biochim Biophys Acta. 2014 Dec;1840(12):3311-9
pubmed: 25152356
Int J Mol Sci. 2020 Nov 03;21(21):
pubmed: 33153232
Biomed Pharmacother. 2020 Feb;122:109772
pubmed: 31918290
Clin J Am Soc Nephrol. 2018 Oct 8;13(10):1605-1611
pubmed: 29615394
Am J Physiol Renal Physiol. 2023 Oct 1;325(4):F503-F518
pubmed: 37589054
Antioxidants (Basel). 2020 Dec 31;10(1):
pubmed: 33396350
Ren Fail. 2019 Nov;41(1):955-966
pubmed: 31658856
Acta Biochim Biophys Sin (Shanghai). 2022 Jan 25;54(1):1-11
pubmed: 35130610
Med Sci Monit. 2016 Dec 25;22:5109-5115
pubmed: 28013315
Front Immunol. 2021 Mar 31;12:649463
pubmed: 33868286
J Clin Med. 2021 Aug 25;10(17):
pubmed: 34501245
J Nutr Biochem. 2012 Jul;23(7):768-76
pubmed: 21889885
Biochim Biophys Acta. 2006 Jul;1763(7):747-58
pubmed: 16828895
Int J Mol Sci. 2022 Feb 16;23(4):
pubmed: 35216290
Cancer Cell Int. 2022 Nov 24;22(1):368
pubmed: 36424626
Kidney Int. 2019 Nov;96(5):1083-1099
pubmed: 31443997
Lancet. 2015 Oct 10;386(10002):1465-71
pubmed: 26466051
Evid Based Complement Alternat Med. 2018 Sep 30;2018:6057579
pubmed: 30364020
Molecules. 2022 Mar 21;27(6):
pubmed: 35335387
J Cheminform. 2012 Aug 13;4(1):17
pubmed: 22889332
Eur J Pharmacol. 2018 Aug 15;833:307-313
pubmed: 29920283
Intensive Care Med. 2009 Aug;35(8):1471-8
pubmed: 19529910
Phytomedicine. 2023 Mar;111:154668
pubmed: 36657316
Hypertension. 2017 Feb;69(2):339-348
pubmed: 27993957
Oxid Med Cell Longev. 2020 Jul 28;2020:6123459
pubmed: 32774680
Molecules. 2021 Sep 30;26(19):
pubmed: 34641472
Antioxidants (Basel). 2020 Dec 14;9(12):
pubmed: 33327548
Front Endocrinol (Lausanne). 2023 Mar 20;14:1139444
pubmed: 37020591
Xenobiotica. 2021 Jun;51(6):728-736
pubmed: 33874851

Auteurs

Xiaoli Yi (X)

Translational Medicine Centre, Jiangxi University of Chinese Medicine, Nanchang 330002, China.

Chuanming Xu (C)

Translational Medicine Centre, Jiangxi University of Chinese Medicine, Nanchang 330002, China.

Jing Yang (J)

Translational Medicine Centre, Jiangxi University of Chinese Medicine, Nanchang 330002, China.

Chao Zhong (C)

Translational Medicine Centre, Jiangxi University of Chinese Medicine, Nanchang 330002, China.

Huiru Yang (H)

Translational Medicine Centre, Jiangxi University of Chinese Medicine, Nanchang 330002, China.

Le Tang (L)

Translational Medicine Centre, Jiangxi University of Chinese Medicine, Nanchang 330002, China.

Shanshan Song (S)

Translational Medicine Centre, Jiangxi University of Chinese Medicine, Nanchang 330002, China.

Jun Yu (J)

Center for Metabolic Disease Research, Department of Cardiovascular Sciences, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH